Loading...
Inhibition of cholesteryl ester transfer protein (CETP), a plasma glycoprotein that aids in the transfer of cholesterol esters from HDL cholesterol to apolipoprotein B-containing lipoproteins, has raised HDL levels in animals. In a single-blind, randomized trial sponsored partly by the manufacturer of a novel CETP inhibitor (torcetrapib), researchers enrolled 19 people (17 men) with HDL levels <40 mg/dL. All 19 received placebo for 4 weeks; for the next 4, ten participants received torcetrapib alone (120 mg/day) and nine received torcetrapib plus atorvastatin (20 mg/day). Six people in the torcetrapib-alone group received 120 mg twice daily of torcetrapib for another 4 weeks.
From the end of the placebo phase to the end of treatment, CETP ac…